1.Clinical evidence of therapy of IgA nephropathy.
Wei-Hua GAN ; Ai-Qing ZHANG ; Gui-Xia DING ; Jing GONG
Chinese Journal of Contemporary Pediatrics 2007;9(2):101-103
Angiotensin-Converting Enzyme Inhibitors
;
therapeutic use
;
Anticoagulants
;
therapeutic use
;
Cyclophosphamide
;
therapeutic use
;
Cyclosporine
;
therapeutic use
;
Fish Oils
;
therapeutic use
;
Glomerulonephritis, IGA
;
therapy
;
Glucocorticoids
;
therapeutic use
;
Humans
;
Mycophenolic Acid
;
analogs & derivatives
;
therapeutic use
2.Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients.
Kui QIU ; Hui TIAN ; Wei WANG ; Xiao-Peng HU ; Xiao-Bei LI ; Li-Li GONG ; Wei LUO ; Li-Hong LIU ; Xiao-Dong ZHANG ; Hang YIN
Chinese Medical Journal 2012;125(23):4226-4232
BACKGROUNDMycophenolic acid (MPA) as an anti-proliferative immune-suppressive agent is used in the majority of immunosuppressive regimens in solid organ transplantation. This study aimed to investigate the pharmacokinetic (PK) characteristics of enteric-coated mycophenolate sodium (EC-MPS) and area under the curve (AUC) from 0 to 12 hours with limited sampling strategies (LSSs) in Chinese renal transplant recipients.
METHODSThis study was conducted in 10 Chinese renal transplant patients receiving living donor and treated with EC-MPS, cyclosporine, and corticosteroids. MPA concentrations were measured by enzyme multiplied immunoassay technique (EMIT). Whole 12-hour PK profiles were obtained on Day 4 after operation. LSSs with jackknife technique, multiple stepwise regression analysis, and Bland-Altman analysis were developed to estimate MPA AUC.
RESULTSThe mean maximum plasma concentration, the mean time for it to reach peak (T(max)), and the mean MPA AUC were (11.38 ± 2.49) mg/L, (4.85 ± 3.32) hours, and (63.19 ± 13.54) mg×h×L(-1), respectively. Among the 10 profiles, MPA AUC of four patients was significantly higher than that of the other six patients, and the corresponding T(max) was significantly longer than that of the other six patients. No patient exhibited a second peak caused by enterohepatic recirculation. The best models were as follows: 27.46 + 0.94C(3) + 3.24C(8) + 2.81C(10) (r(2) = 0.972), which was used to predict AUC of fast metabolizer with a mean prediction error (MPE) of -0.21% and a mean absolute prediction error (MAE) of 2.59%; 36.65 + 3.08C(8) + 5.30C(10) - 4.04C(12) (r(2) = 0.992), which was used to predict AUC of slow metabolizer with a MPE of 0.58% and a MAE of 1.95%.
CONCLUSIONSThe PKs of EC-MPS had a high variability among Chinese renal transplant recipients. The preliminary PK data indicated the existence of slow and fast metabolizer. These findings may be associated with the enterohepatic recirculation.
Adrenal Cortex Hormones ; therapeutic use ; Adult ; Aged ; Cyclosporine ; therapeutic use ; Female ; Humans ; Kidney Transplantation ; methods ; Male ; Middle Aged ; Mycophenolic Acid ; analogs & derivatives ; pharmacokinetics ; therapeutic use ; Young Adult
3.Clinical efficacy of mycophenolate mofetil in the treatment of systemic-onset juvenile idiopathic arthritis.
Tong-Xin HAN ; Cai-Feng LI ; Jiang WANG ; Wei-Ying KUANG ; Yi-Fang ZHOU ; Jiang-Hong DENG
Chinese Journal of Contemporary Pediatrics 2013;15(8):666-670
OBJECTIVETo evaluate the clinical efficacy of mycophenolate mofetil (MMF) in the treatment of systemic-onset juvenile idiopathic arthritis (SoJIA).
METHODSThirty-five patients with a confirmed diagnosis of SoJIA who had received initial treatment were randomly divided into control (n=15), MMF1 (n=7) and MMF2 groups (n=13). The control group received conventional treatment, the MMF1 group received MMF after 2 weeks of conventional treatment that had not led to remission, and the MMF2 group received combination therapy with non-steroidal anti-inflammatory drugs, prednisone and MMF. Symptoms, signs, laboratory indices, and adverse events were observed after 2, 4, and 12 weeks of treatment, and follow-up was performed for 3-6 months.
RESULTSBefore treatment, the MMF2 group had a significantly longer disease course than the control group (P<0.05). After 2 weeks of treatment, the MMF1 and MMF2 groups had a significantly lower prednisone dose and erythrocyte sedimentation rate (ESR) than the control group (P<0.05). The MMF1 group had significantly higher body temperature than the other two groups (P<0.05). After 4 weeks of treatment, the MMF1 group had a significantly lower prednisone dose and ESR than the control group (P<0.05). The MMF2 group had a significantly lower prednisone dose, body temperature (recovery to normal), white blood cell count, ESR and serum ferritin concentration than the control group (P<0.05). Body temperature was significantly lower in the MMF2 group than in the MMF1 group (P<0.05). No adverse events were observed in either the MMF1 or MMF2 groups during treatment.
CONCLUSIONSCombination therapy with MMF can lead to better control of the patient's condition, more rapid relief of clinical symptoms and reduced glucocorticoid dose. The therapy with MMF is safe in children.
Arthritis, Juvenile ; blood ; drug therapy ; Blood Sedimentation ; Child, Preschool ; Female ; Humans ; Immunosuppressive Agents ; therapeutic use ; Male ; Mycophenolic Acid ; analogs & derivatives ; therapeutic use ; Prednisone ; therapeutic use
6.A Case of Minimal Change Disease Treated Successfully with Mycophenolate Mofetil in a Patient with Systemic Lupus Erythematosus.
Young Hoon HONG ; Dae Young YUN ; Yong Wook JUNG ; Myung Jin OH ; Hyun Je KIM ; Choong Ki LEE
The Korean Journal of Internal Medicine 2011;26(4):470-473
The World Health Organization classifies lupus nephritis as class I to V or VI. However, a few cases of minimal change glomerulopathy have been reported in association with systemic lupus erythematosus (SLE). Mycophenolate mofetil has been shown to be effective for treatment of minimal change disease and lupus nephritis. A 24-year-old woman diagnosed with SLE five years prior to presentation complained of a mild generalized edema. The urinalysis showed microscopic hematuria and proteinuria. The assessed amount of total proteinuria was 1,618 mg/24 hours. A renal biopsy demonstrated diffuse fusion of the foot processes of podocytes on electron microscopy. Mycophenolate mofetil was started in addition to the maintenance medications of prednisolone 10 mg/day and hydroxychloroquine 400 mg/day. After six months of treatment, the microscopic hematuria and proteinuria resolved, and the total urine protein decreased to 100 mg/24 hours.
Antirheumatic Agents/therapeutic use
;
Female
;
Glucocorticoids/therapeutic use
;
Humans
;
Hydroxychloroquine/therapeutic use
;
Immunosuppressive Agents/*therapeutic use
;
Lupus Erythematosus, Systemic/complications/*pathology
;
Mycophenolic Acid/*analogs & derivatives/therapeutic use
;
Nephrosis, Lipoid/*drug therapy/etiology/pathology
;
Prednisone/therapeutic use
;
Young Adult
7.Clinical application and side effects of immunosuppressant.
Chinese Journal of Contemporary Pediatrics 2007;9(2):107-112
Adjuvants, Immunologic
;
adverse effects
;
therapeutic use
;
Azathioprine
;
adverse effects
;
therapeutic use
;
Cyclosporine
;
adverse effects
;
therapeutic use
;
Glucocorticoids
;
adverse effects
;
therapeutic use
;
Humans
;
Mycophenolic Acid
;
adverse effects
;
analogs & derivatives
;
therapeutic use
;
Tacrolimus
;
adverse effects
;
therapeutic use
9.Mycophenolate mofetil or tacrolimus compared with azathioprine in long-term maintenance treatment for active lupus nephritis.
Qianying ZHANG ; Peng XING ; Hong REN ; Xiaonong CHEN ; Jingyuan XIE ; Wen ZHANG ; Pingyan SHEN ; Xiao LI ; Nan CHEN
Frontiers of Medicine 2022;16(5):799-807
This study aimed to evaluate the efficacy and safety of mycophenolate mofetil (MMF) or tacrolimus (TAC) compared with azathioprine (AZA) as maintenance therapy for active lupus nephritis (ALN). Patients with ALN who responded to 24 weeks of induction treatment were enrolled. Patients who received MMF or TAC as induction therapy continued MMF or TAC treatment during the maintenance period, whereas those who received intravenous cyclophosphamide were subjected to AZA treatment. The primary endpoint was the incidence of renal relapse. Secondary endpoints included extrarenal flares and composite endpoints (deaths, end-stage renal disease, or doubling of serum creatinine levels). A total of 123 ALN patients (47 in the MMF group, 37 in the TAC group, and 39 in the AZA group) were enrolled. The median follow-up time was 60 months. Ten MMF-treated patients, ten TAC-treated patients, and eight AZA-treated patients experienced renal relapses (P = 0.844). The cumulative renal relapse rates in the MMF group (P = 0.934) and TAC group (P = 0.673) were similar to the renal relapse rate in the AZA group. No significant difference in the incidence of severe adverse event was observed among the groups. Long-term maintenance therapies with MMF or TAC might have similarly low rates of renal relapse and similar safety profiles compared with AZA.
Humans
;
Mycophenolic Acid/adverse effects*
;
Azathioprine/adverse effects*
;
Tacrolimus/therapeutic use*
;
Lupus Nephritis/complications*
;
Immunosuppressive Agents
;
Treatment Outcome
;
Recurrence
10.Impact of mycophenolate mofetil prophylaxis duration on acute graft-versus-host disease after haploidentical stem cell transplantation.
Yu Qian SUN ; Xiao Jun HUANG ; Lan Ping XU ; Xiao Hui ZHANG ; Chen Hui YAN ; Kai Yan LIU ; Yu WANG
Chinese Journal of Hematology 2018;39(4):286-291
Objective: To investigate the impact of mycophenolate mofetil (MMF) prophylaxis duration on acute graft-versus-host disease (aGVHD) after haploidentical stem cell transplantation (haplo-HSCT) using 'Beijing Protocol'. Methods: Adult patients (≥14 years) received haplo-HSCT in Peking University Institute of Hematology from Sep, 2016 to Mar, 2017 were retrospectively reviewed if they fulfilled the criterias: ①diagnosed with hematological maligancies; ②standard-risk status at haplo-HSCT. A total of 237 patients [including 102 patients with long MMF duration (defined as started on day -9 with 100 mg/d, adjusted to 500 mg/d from day +30 and discontinued on day +45 to +60 or occurrence of CMV/EBV reactivation or late-onset hemorrhagic cytitis), and 135 patients with short MMF duration (defined as started on day -9 with 500 mg/d and discontinued on the day achieved neutrophil engraftment)] were reviewed. The incidence of aGVHD, virus infection and overall survival (OS) were compared between the two groups. Results: The median durations of MMF prophylaxis of long and short duration groups were 27(7-71) and 15(9-24) days, respectively after haplo-HSCT. There were no differences of baseline characteristics (including sex, patient age, disease, mismatched HLA loci, donor-recipient relation, donor-recipient sex and donor age) between the two groups. The incidences of the grade Ⅱ-Ⅳ and Ⅲ/Ⅳ aGVHD in long and short duration groups were 31.1% versus 17.6% (P=0.018) and 7.4% verus 7.8% (P=0.900), respectively. The duration of MMF prophylaxis was not found to be associated with gradeⅡ-Ⅳ aGVHD by the multivariate analysis. There were no significant differences in terms of CMV viremia, EBV viremia, hemorrhagic cytitis and OS between the two groups. Conclusion: Prophylaxis with short duration MMF in the setting of 'Beijing protocol' haplo-SCT was not associated with increased acute GVHD with no impact on OS, which indicated that short duration MMF might be a feasible GVHD prophylaxis regimen.
Graft vs Host Disease
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Immunosuppressive Agents
;
Mycophenolic Acid/therapeutic use*
;
Retrospective Studies
;
Transplantation Conditioning